MOLECULAR PARTNERS AG -ADR (MOLN) Stock News
NASDAQ:MOLN - Nasdaq - US60853G1067 - ADR - Currency: USD
MOLN Latest News, Press Relases and Analysis
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin...
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to...
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic...
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
Clinical update from ongoing MP0533 phase 1/2a dose escalation study confirms overall acceptable safety profile observed so far and initial antileukemic...
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress;...
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG...
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs...
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and...
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on...
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth...
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 ...
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning!